Emerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
|
|
|
- Robert Dennis Clark
- 6 years ago
- Views:
Transcription
1 Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC) Natalizumab (CD) Anti-TNF/ Moderate Corticosteroid Aminosalicylate/ Mild Aminosalicylate Oral/Topical/Combo Aminosalicylate ate Oral/Topical/Combo Maintenance Therapy is stepped up according to severity at presentation or failure at prior step 1
2 New and Near Future Therapies for Ulcerative Colitis Budesonide MMX Golimumab Vedolizumab Tofacitanib ib (phase II) Disease Severity at Presentation and Maintenance for Mild- Moderate UC: Where are the gaps? Severe Moderate Mild Aminosalicylate Oral/Topical/Combo Aminosalicylate ate Oral/Topical/Combo Maintenance 2
3 Budesonide Metabolism and Characteristics 1,2 Oral budesonide ph release: ileum/right colon MMX: pan-colonic ~1% Budesonide ~9% metabolism in the liver o Budesonide characteristics 2 Rectal budesonide Enema/Foam 1 Brattsand R. Can J Gastroenterol.199;4: Gross V. Expert Opin Pharmacother 8;9: o o Non-halogenated corticosteroid, highly lipophilic o Good tissue penetration o 9x greater receptor binding than dexamethasone o Rapidly absorbed in GI tract o Metabolites are almost inactive o Terminal half-life 2.7 +/-.6 hours Needs specifically designed release system CORE I and II: Budesonide MMX Primary Endpoint Combined Clinical and Endoscopic Remission * ** *** N=121 N=89 N=21 N=123 N=19 N=232 N=121 N=19 N=23 N=124 N=13 *P=.143 **P=.47 ***P=.2 ASA=Asacol; Ent=Entocort; B-MMX=budesonide MMX Sandborn WJ et al. Gastroenterology 11;1 (Suppl): S124; Sandborn WJ et al. Gastroenterology 11;1 (Suppl): S65; Sandborn WJ et al. Am J Gastroenterol 11;16 (Suppl): S485 3
4 Moderate-Severe UC: Where are the gaps? Disease Severity at Presentation Colectomy Severe Anti-TNF +/IS Cyclosporine Anti-TNF/ Moderate Corticosteroid Aminosalicylate/ Mild Maintenance Therapy is stepped up according to severity at presentation or failure at prior step What is the Optimal Positioning of MMX- Budesonide in Mild-Moderate UC? Disease Severity at Presentation Severe Moderate Mild MMX-Budesonide Before 5-ASA? Tested Aminosalicylate Oral/Topical/Combo With 5-ASA? Before prednisone? Maintenance? Maintenance? Aminosalicylate/ Corticosteroid Aminosalicylate ate Oral/Topical/Combo Maintenance Therapy is stepped up according to severity at presentation or failure at prior step 4
5 Three classes of anti-tnf: Fusion protein, antibodies and PEGylated Fab' fragment Etanercept Receptor Infliximab Fab Adalimumab Golimumab Fab Certolizumab pegol IgG1 Fc IgG1 Fc PEG Human recombinant receptor/fc fusion protein Chimeric Monoclonal antibody Human PEGylated humanized Fab fragment 2 kda PEG UC: Comparing ACT (Infliximab), Pursuit (Adalimumab) and Ultra (Golimumab) Clinical Remission 6-8 weeks Patients failing 5-ASA/Steroids/IS Infliximab Adalimumab Golimumab weeks 5
6 PURSUIT-Maintenance: Clinical Response* Through Week 54 Among Subjects in Clinical Response to Golimumab 1 Subjects (%) P= P< Placebo 5 mg 1 mg (n=156) (n=153) (n=154) Golimumab *Defined as a decrease from Week of an induction study in the Mayo score by 3% and 3 points, with either a decrease from baseline in the rectal bleeding subscore of 1 or a rectal bleeding subscore of or 1 Sandborn WJ et al. Gastroenterology. 13;1.153/j.gastro Infliximab + Azathioprine vs Infliximab vs Azathioprine: The SUCCESS Study *P<.5 compared to IFX; #P<.5 compared to AZA 77 # 69 5 * # # IFX+AZA (n=78) IFX (n=77) AZA (n=66) Steroid-free remission Response Mucosal Healing AZA=azathioprine; IFX=infliximab Panccione R et al. DDW 11; Abstract 835 6
7 What is the optimal positioning for Golimumab in UC? Disease Severity at Presentation Unlikely in Severe/Fulminant Colectomy Severe Golimumab Anti-TNF +/IS Cyclosporine Anti-TNF/ Moderate Possible Tested Corticosteroid Aminosalicylate/ Mild With/Without IS? Maintenance Therapy is stepped up according to severity at presentation or failure at prior step Moderate-Severe UC: Where are the gaps? Disease Severity at Presentation Colectomy Severe Anti-TNF +/IS Cyclosporine Anti-TNF/ Moderate Corticosteroid Aminosalicylate/ Mild Maintenance Therapy is stepped up according to severity at presentation or failure at prior step 7
8 Janus Kinase Pathway Janus kinase inhibitor Targets a specific intracellular signaling cascade-jak/stat pathway The JAK family binds multiple cytokine receptors including: IL2/IL4/IL7/IL9/IL12 (JAK3) IFNs Tofacitinib is JAK3 inhibitor used for psoriasis and rheumatoid arthritis. TNF, tumor necrosis factor; RA, rheumatoid arthritis Shuai K et al. Nat Rev Immunol 3;11:9. Phase 2 Study of Tofacitinib (CP-69,55), an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis Sandborn W et al. N Engl J Med 12 SAFETY? Sandborn W et al. N Engl J Med 12 8
9 L-selectin Recruitment of Neutrophils Into Inflamed Tissue β 2 -integrin activation E/P-selectin IL-8 PAF ICAM-1 Endothelium Rolling Tight adhesion Transmigration Van Deventer SJ. Gut 2;3: Endothelial and Leukocyte Adhesion: α4 Integrins α4 β1/β7 Leukocyte membrane glycoproteins β1 and β7 subunits Interact with endothelial ligands VCAM-1, fibronectin, and MAdCAM-1 Mediate leukocyte adhesion and trafficking Springer TA. Cell. 1994;76:31-314; Butcher EC et al. Science 1996;272:
10 Therapeutic Targets LEUCOCYTE Leukocyte Adhesion CD 11a/CD18 NATALIZUMAB VEDOLIZUMAB CCX282-B ISIS-232 α4β1 (VLA-4) α4β7 CCR9 MAdCAM mab (PF ) rhumab Beta 7 CCL-25 ICAM-1 MadCAM-1 VCAM-1 Adapted from Danese S. Gut 11;6: ACTIVATED INTESTINAL MICROVASCULAR ENDOTHELIAL CELLS Vedolizumab Phase III: Study Design Phase Week Week 6 Maintenance Phase Week 6 Week 52 Cohort 1 Blinded N=374 Placebo N=149 VDZ N=225 No Placebo N=149 VDZ N=373 Screening, Enrollment No Cohort 1 complete? Week 6: Responder? Yes Placebo N=126 VDZ Q8 wks N=122 Week 52 Assessments Yes Cohort 2 Open-Label N=521 VDZ N=521 VDZ Q4 wks N=125 Corticosteroid Tapering* *Responders began tapering regimen at 6 weeks; others, as soon as a clinical response was achieved. Feagan BG et al. New Engl J Med 13;369:
11 Clinical Response, Clinical Remission, Mucosal Healing at 6 Weeks, ITT Population % CI: P< Placebo Vedolizumab P= P=.1.9 Clinical Response Clinical Remission Mucosal Healing Δ , 31.7 Δ , 18.3 Δ , 25.9 Feagan BG et al. New Engl J Med 13;369: Clinical Response, Clinical Remission, Mucosal Healing at 6 Weeks, ITT Population % CI: P< Placebo Vedolizumab P= P=.1.9 Clinical Response Clinical Remission Mucosal Healing Δ , 31.7 Δ , 18.3 Δ , 25.9 Feagan BG et al. New Engl J Med 13;369:
12 Clinical Response, Clinical Remission, Mucosal Healing at 6 Weeks, ITT Population % CI: P< Placebo Vedolizumab P= P=.1.9 Clinical Response Clinical Remission Mucosal Healing Δ , 31.7 Δ , 18.3 Δ , 25.9 Feagan BG et al. New Engl J Med 13;369: Clinical Remission, Durable Clinical Response at 52 Weeks by Prior TNF Antagonist Exposure Prior Anti-TNF Antagonist Exposure (n=149) VDZ/PBO VDZ/VDZ Q8W VDZ/VDZ Q4W Clinical Remission Durable Clinical Response Clinical Remission Patients Without TNF Antagonist Exposure (n=224) Durable Clinical Response Mean Δ% vs VDZ/PBO (95% CI) VDZ/VDZ Q8W: 25.4 (5.1, 43.8) VDZ/VDZ Q4W: 29.7 (1.3, 47.7) 24.9 (7.1, 42.6) 27. (9.4, 44.6) 26.8 (12.4, 41.2) 29. (14.6, 43.3) 38.7 (24., 53.4) 29.6 (14.6, 44.6) PBO=placebo; VDZ=vedolizumab Feagan BG et al. New Engl J Med 13;369:
13 Clinical Remission, Durable Clinical Response at 52 Weeks by Prior TNF Antagonist Exposure Prior Anti-TNF Antagonist Exposure (n=149) VDZ/PBO VDZ/VDZ Q8W VDZ/VDZ Q4W Clinical Remission Durable Clinical Response Clinical Remission Patients Without TNF Antagonist Exposure (n=224) Durable Clinical Response Mean Δ% vs VDZ/PBO (95% CI) VDZ/VDZ Q8W: 25.4 (5.1, 43.8) VDZ/VDZ Q4W: 29.7 (1.3, 47.7) 24.9 (7.1, 42.6) 27. (9.4, 44.6) 26.8 (12.4, 41.2) 29. (14.6, 43.3) 38.7 (24., 53.4) 29.6 (14.6, 44.6) PBO=placebo; VDZ=vedolizumab Feagan BG et al. New Engl J Med 13;369: What is the optimal positioning for Vedolizumab in UC? Disease Severity at Presentation Severe Vedolizumab Before Anti-TNFs? Anti-TNF +/IS Cyclosporine Colectomy Anti-TNF/ Moderate Before Steroids? Tested Corticosteroid Aminosalicylate/ Mild Maintenance Therapy is stepped up according to severity at presentation or failure at prior step 13
14 Vedolizumab Crohn s Disease Ustekinemab (phase II) Where are the Gaps for Crohn s Disease? Disease Severity at Presentation Severe Anti-TNF +/IS Natalizumab (CD) Anti-TNF/ Moderate Corticosteroid Aminosalicylate/ Mild Aminosalicylate (Oral/Topical/Combo) Budesonide Aminosalicylate ate Oral/Topical/Combo Maintenance Therapy is stepped up according to severity at presentation or failure at prior step 14
15 Vedolizumab for CD and Maintenance Phase Week Week 6 Maintenance Phase Week 6 Week 52 Screening, Enrollment Cohort 1 Placebo Placebo Blinded N=148 N=148 N=368 No Cohort 1 complete? VDZ N=2 Week 6: Responder? No Yes VDZ N=56 Placebo N=153 VDZ Q8 wks N=154 Week 52 Assess -ments Yes Cohort 2 Open-Label N=747 VDZ N=747 VDZ Q4 wks N=154 Corticosteroid Tapering* *Responders began tapering regimen at 6 weeks; others, as soon as a clinical response was achieved. VDZ=vedolizumab Sandborn WJ et al. New Engl J Med 13;369: Clinical Remission and CDAI-1 Response at Week 6 8 Placebo Vedolizumab 6 P=.2 P= Clinical Remission CDAI-1 Response Mean Δ% vs PBO (95% CI) 7.8 (1.2, 14.3) 5.7 ( 3.6, 15.) PBO=placebo; VDZ=vedolizumab Sandborn WJ et al. New Engl J Med 13;369:
16 1 8 6 Primary and Secondary Outcomes at 52 Weeks Primary Outcome Secondary Outcomes VDZ/PBO VDZ/VDZ Q8W VDZ/VDZ Q4W Clinical Remission CDAI-1 Response CS-Free Remission Durable Remission Mean Δ% vs VDZ/PBO P<.1 vs placebo; P<.5 vs placebo CS=corticosteroid; VDZ=vedolizumab Sandborn WJ et al. New Engl J Med 13;369: Clinical Remission, CDAI-1 Response at 52 Weeks by Prior TNF Antagonist Exposure Maintenance ITT Population* Patients With Prior Anti-TNFα Exposure (n=253) VDZ/PBO VDZ/VDZ Q8W VDZ/VDZ Q4W Patients Without Prior Anti-TNFα Exposure (n=8) Clinical Remission CDAI-1 Response CS-Free Remission Durable Remission Mean Δ% vs VDZ/PBO (95% CI) VDZ/VDZ Q8W: 12.5 (.1, 25.) VDZ/VDZ Q4W: 1.6 ( 2., 23.2) 7.5 ( 5.8,.8) 15.4 (1.5, 29.3) 24.8 (8.9,.6) 19.7 (4.2, 35.2) 22.6 (6.3, 38.9) 15.5 (.7, 31.7) VDZ=vedolizumab Sandborn WJ et al. New Engl J Med 13;369:
17 Vedolizumab Phase 3 Trial in CD CDAI-1 Response ITT Population 1 Anti-TNFα Failure Population (n=315) Overall Population (n=416) 8 6 Placebo Vedolizumab 39.2* Week 6 Week 1 Week 6 Week 1 CDAI-1 Response *P=.11 vs placebo; P<.1 vs placebo; P=.2 vs placebo PBO=placebo; VDZ=vedolizumab Sands B et al. Presented at ECCO 13. IL-12 and IL-23 Cytokines and Receptors Are First Cousins IL-12 Presky DH et al. Proc Natl Acad Sci U S A. 1996;93:12. IL-23 Oppmann B et al. Immunity. ;13:715. p p35 p19 p NK or T cell membrane Chua AO et al. J Immunol. 1995;155:4286. Parham C et al. J Immunol. 2;168:5699. Intracellular Signaling (eg, STAT-P) 17
18 Anti-p Mechanism of Action IL-12 Presky DH et al. Proc Natl Acad Sci U S A. 1996;93:12. Oppmann B et al. Immunity. ;13:715. IL-23 p p35 Ustekinumab p19 p NK or T cell membrane Chua AO et al. J Immunol 1995;155:4286. No Signal Parham C et al. J Immunol. 2;168:5699. Ustekinumab for Crohn s disease: blocks IL-12/IL-23 Clinical Response and Remission at Weeks 6 and Placebo UST 1 mg/kg UST 3 mg/kg UST 6 mg/kg UST combined 1 Clinical Response Week 6 (primary end point) Clinical Response Week 8 Clinical Remission Week 6 Clinical Remission Week 8 *P<.5 Sandborn W, et al. N Engl J Med 12 Oct 18;367(16):
19 Disease Severity at Presentation Positioning Vedolizumab and Ustekinemab in Crohn s? Vedolizumab? Natalizumab (CD) Severe Ustekinemab? Anti-TNF +/IS Anti-TNF/ Moderate Corticosteroid Aminosalicylate/ Mild Aminosalicylate Oral/Topical/Combo Aminosalicylate ate Oral/Topical/Combo Maintenance Therapy is stepped up according to severity at presentation or failure at prior step Positioning New and Future Therapies for UC MMX Budesonide Clinical Trials Position as First Line Clinical Practice more likely after 5-ASA Potential for maintenance? 19
20 Positioning New and Future Therapies for UC Golimumab Clinical Trials in Mod-Severe Outpatients Clinical Practice as a sub-q alternative anti- TNF Potential for therapeutic Drug monitoring Positioning New and Future Therapies for UC Vedolizumab Clinical Trials in Mod-Severe Outpatients failing Steroids/IS/Anti-TNF Clinical Practice as & Maintenance as Anti-TNF alternative No PML in clinical trials but likely to have FDA monitoring requisites
21 Positioning New and Future Therapies for Crohn s Disease Vedolizumab Before (?)/After (?) anti-tnf Maintenance benefits> Earlier disease? Steroid induction? Ustekinemab How to dose? Before (?)/After(?) anti-tnf 21
Positioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
Update on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
Vedolizumab: policing leukocyte traffic
Oxford Inflammatory Bowel Disease MasterClass Vedolizumab: policing leukocyte traffic Dr Brian Feagan, London, Canada Vedolizumab : Policing Lymphocyte Traficking Brian G. Feagan Professor of Medicine,
Therapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
New and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
New treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
Biologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
Selection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
Recent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
Severe IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
September 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
Gionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
Medical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
Selective leucocyte trafficking inhibitors for treatment of IBD
Selective leucocyte trafficking inhibitors for treatment of IBD Séverine Vermeire MD, PhD Department of Gastroenterology University Hospitals Leuven Belgium Migration of Leucocytes plays a key role in
Selby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
Efficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
Future Therapies in IBD. William J. Sandborn, M.D. Mayo Clinic, Rochester, Minnesota
Future Therapies in IBD William J. Sandborn, M.D. Mayo Clinic, Rochester, Minnesota Korzenik et al. Nature Reviews Drug Discovery 5, 197 209 (March 2006) doi:10.1038/nrd1986 Therapies for IBD: The Pipeline
Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien The Biologic s evolution From availabilitydriven
Progress in Inflammatory Bowel Disease
Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,
Emerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
Ulcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
Pharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
Pharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
Current and Emerging Biologics for Ulcerative Colitis
Gut and Liver, Vol. 9, No. 1, January 2015, pp. 18-27 Review Current and Emerging Biologics for Ulcerative Colitis Sung Chul Park* and Yoon Tae Jeen *Division of Gastroenterology and Hepatology, Department
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
Personalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
Ali Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
Immunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
How to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
Therapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
Efficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
Pharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
The Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
Case Example: Exposure Response to Support Extrapolation of Efficacy in Pediatric Ulcerative Colitis
Case Example: Exposure Response to Support Extrapolation of Efficacy in Pediatric Ulcerative Colitis Kerry Jo Lee, MD Medical Officer Division of Gastroenterology and Inborn Error Products Office of New
Indications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
Anti tumor necrosis factor (TNF) agents have
Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical
Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF
Managing Complications of IBD and Its Therapies David T. Rubin, MD, AGAF Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Medicine
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
Agenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
Advances in the development of new biologics in inflammatory bowel disease
INVITED REVIEW Annals of Gastroenterology (2016) 29, 1-6 Advances in the development of new biologics in inflammatory bowel disease Bella Ungar, Uri Kopylov Sheba Medical Center, Tel Hashomer and Sackler
Personalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
ENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
Medical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
New and Emerging Therapies in IBD. Sarah Streett MD, AGAF Clinical Associate Professor of Medicine Stanford University
New and Emerging Therapies in IBD Sarah Streett MD, AGAF Clinical Associate Professor of Medicine Stanford University New and Emerging Therapies in IBD I have no relevant financial disclosures. IBD is
Disease Management Strategies for Moderate to Severe IBD in Adults
Disease Management Strategies for Moderate to Severe IBD in Adults Alyssa Parian, MD Assistant Professor of Medicine Johns Hopkins University April 21, 2016 Outline Overview of IBD Treatments (Benefits/Risks)
Latest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
Join the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
Title: Author: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
ADHESION MOLECULES AS A THERAPEUTIC TARGET IN IBD
ADHESION MOLECULES AS A THERAPEUTIC TARGET IN IBD Raquel F. Leal, Azucena Salas Institut d investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Center Esther Koplowitz, Barcelona, Spain Disclosure: No
Use of extrapolation in small clinical trials:
Use of extrapolation in small clinical trials: Infliximab for pediatric ulcerative colitis Jessica J. Lee, MD, MMSc Medical Officer Division of Gastroenterology and Inborn Errors Products CDER/ FDA 1 Learning
Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
COPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
Positioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
Moderately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
Optimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
Managing Crohn s Disease and Ulcerative Colitis
Managing Crohn s Disease and Ulcerative Colitis Samir A. Shah, MD, FACG, FASGE, AGAF Clinical Professor of Medicine, Brown University Chief of Gastroenterology, The Miriam Hospital Gastroenterology Associates,
Inflammatory bowel disease: Novel therpaies NZ November 2018
Inflammatory bowel disease: Novel therpaies NZ November 2018 Dr Charlie Lees Consultant Gastroenterologist From the Edinburgh IBD Unit at the Western General Hospital History of treatment for IBD 1950s
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
Management of Moderate to Severe Ulcerative Colitis
Management of Moderate to Severe Ulcerative Colitis Neilanjan Nandi, MD Assistant Professor of Medicine Associate Program Director Division of Gastroenterology Drexel University College of Medicine Hahnemann
IBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh
IBD Biologicals and Novel therapeutic regimes Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh 1 Treatment aims in IBD Traditional treatment goals of IBD Control of symptoms?improvement
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
Clinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265
Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
Long-term Efficacy of Vedolizumab for Crohn s Disease
Journal of Crohn's and Colitis, 217, 412 424 doi:1.193/ecco-jcc/jjw176 Advance Access publication September 28, 216 Original Article Original Article Long-term Efficacy of Vedolizumab for Crohn s Disease
Mono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
U of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
ENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 285.8 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
ENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
Mucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
Achieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
Future Directions in IBD: Treatments & Approaches JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER APRIL 29, 2018
Future Directions in IBD: Treatments & Approaches JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER APRIL 29, 2018 Why do pharmaceuticals dominate IBD therapy discussions?
Op#mal Therapy in IBD: Where Are We Now?
Op#mal Therapy in IBD: Where Are We Now? Brian G. Feagan MD Professor of Medicine, Epidemiology and Biosta;s;cs Western University Senior Scien;fic Director, Robarts Clinical Trials, London, Ontario, Canada
Medicine OPEN. Observational Study. 1. Introduction
Observational Study Medicine OPEN Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy Tsutomu Mizoshita,
FOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015
Contact: Ross Selby Takeda UK Ltd Email ross.selby@takeda.com News Release FOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015 World s first gut-selective treatment for ulcerative colitis
I nuovi farmaci biologici: anche nell'anziano?
LE MALATTIE INFIAMMATORIE CRONICHE INTESTINALI NELL ANZIANO I nuovi farmaci biologici: anche nell'anziano? ANNA KOHN (Roma) increasing incidence Jeuring SFG, Inflamm Bowel Dis 2016 IBD Prevalence on December
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
Extrapolation & Pediatric Development: A case study from pediatric Ulcerative Colitis Richard Strauss, MD
Extrapolation & Pediatric Development: A case study from pediatric Ulcerative Colitis Richard Strauss, MD Immunology Clinical Development Janssen Research and Development Agenda Rationale for extrapolation
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
Evidence review for Surrey Prescribing Clinical Network SUMMARY
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Surrey Prescribing Clinical Network Medicine
Dr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant: